UMass Memorial Hospital
Welcome,         Profile    Billing    Logout  
 7 Trials 
30 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Muehlschlegel, Susanne
NCT05671874: Feasibility of a Digital Goals-of-Care Decision Aid for Clinicians and Families of Patients With SABI

Recruiting
N/A
50
US
Web/mobile/tablet-based digital decision aid + communication (DA+C) tool
University of Massachusetts, Worcester, Worcester Polytechnic Institute, National Institutes of Health (NIH), National Institute of Nursing Research (NINR), Johns Hopkins University
Hemorrhagic Stroke, Intracerebral, Acute Ischemic Stroke, Traumatic Brain Injury
06/25
09/25
BOOST3, NCT03754114: Brain Oxygen Optimization in Severe TBI, Phase 3

Recruiting
N/A
1094
Canada, US
ICP + PbtO2 guided management strategy, ICP guided management strategy
University of Michigan, National Institute of Neurological Disorders and Stroke (NINDS), University of Washington, University of Pennsylvania, University of Pittsburgh, Medical University of South Carolina
Brain Injuries, Traumatic
11/27
11/27
Khosroshahi, Arezou
SIRIUS-SLE 2, NCT05624749 / 2022-002690-29: Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus

Recruiting
3
280
Europe, US, RoW
ianalumab, VAY736, placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Systemic Lupus Erythematosus
01/27
01/29
NCT05000216: COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Completed
2
257
US
Moderna mRNA-1273, mRNA-1273 vaccine (Moderna), Moderna COVID-19 Vaccine, SARS-CoV-2 RNA vaccine, COVID-19 vaccine, BNT162b2, mRNA-1273 vaccine (Pfizer/BioNTech), Pfizer-BioNTech COVID-19 vaccine, Ad26.COV2.S, Janssen COVID-19 Vaccine, JNJ-78436735, Continue IS (MMF or MPA), immunosuppressive medication, mycophenolate mofetil, MMF, CellCept®, mycophenolic acid, MPA, Continue IS (MTX), methotrexate, MTX, Continue IS (B cell depletion therapy), mAbs targeting CD19 or CD20, anti-BAFF mAb, Monovalent [B.1.351] CoV2 preS dTM-AS03, Sanofi-GSK COVID-19 Vaccine, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, mRNA-1273 vaccine (Moderna), Bivalent, Moderna COVID-19 Vaccine, Bivalent, SARS-CoV-2 RNA vaccine, Bivalent, COVID-19 vaccine, Bivalent, BNT162b2, Bivalent, mRNA-1273 vaccine (Pfizer/BioNTech), Bivalent, Pfizer-BioNTech COVID-19 vaccine, Bivalent
National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc.
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
06/23
03/24
NCT02633163: Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)

Recruiting
2
81
US
Low Dose Mesenchymal Stem Cells (MSCs), High Dose Mesenchymal Stem Cells (MSCs), Placebo Infusion
Medical University of South Carolina
Systemic Lupus Erythematosus
08/25
02/26
DIVERT, NCT05306873: Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

Terminated
2
9
US
Mycophenolate Mofetil, CellCept, MMF, Placebo for Mycophenolate Mofetil, Voclosporin, Lupkynis, Lupkynis(TM), Placebo for Voclosporin
National Institute of Allergy and Infectious Diseases (NIAID)
Systemic Lupus Erythematosus
04/24
04/24
VIBRANT, NCT05201469: VIB4920 for Active Lupus Nephritis

Recruiting
2
74
US
VIB4920, Placebo for VIB4920
National Institute of Allergy and Infectious Diseases (NIAID)
Lupus Nephritis
08/26
03/27
NCT04918147: Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

Terminated
2
8
US
elotuzumab, BMS-901608, Empliciti®, placebo for elotuzumab, normal saline, methylprednisolone, Solu-Medrol®, diphenhydramine, Benadryl®, acetaminophen, Tylenol®, famotidine, H2 blocker, prednisone, corticosteroid
National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence, Bristol-Myers Squibb, Rho Federal Systems Division, Inc.
IgG4 Related Disease, IgG4-RD
01/24
01/24
RESET-SLE, NCT06121297: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Recruiting
1/2
12
Europe, US
CABA-201
Cabaletta Bio
Systemic Lupus Erythematosus, Lupus Nephritis
12/27
12/27
GLEAM, NCT06294236: Study Evaluating SC291 in Subjects with Severe R/r B-cell Mediated Autoimmune Diseases

Recruiting
1
36
US
SC291, Cyclophosphamide, Fludarabine
Sana Biotechnology
Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis
12/27
03/28
NCT05934149: Lupus Landmark Study: A Prospective Registry and Biorepository

Recruiting
N/A
3500
Canada, US
Lupus Research Alliance
Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Neuropsychiatric Systemic Lupus Erythematosus
12/33
12/33
Rhein, Lawrence
NCT04214834: Trial to Shorten Pharmacologic Treatment of Newborns With Neonatal Opioid Withdrawal Syndrome (NOWS)

Active, not recruiting
3
190
US
Morphine, Methadone
Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Neonatal Opioid Withdrawal Syndrome
01/24
06/26
NCT03321734: Intermittent Hypoxia and Caffeine in Infants Born Preterm

Completed
2
170
US
Caffeine, Placebos
Children's National Research Institute, Boston University, Beth Israel Medical Center, University of Massachusetts, Worcester, American SIDS Institute, Walter Reed National Military Medical Center, Dartmouth-Hitchcock Medical Center, Children's Hospital of Philadelphia, Johns Hopkins All Children's Hospital, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Intermittent Hypoxia
06/23
06/23
NCT06609135: Relationship Between EIT and Respiratory Status in Very Preterm Infants

Completed
N/A
20
US
Sentec LuMon Device (EIT system), Sentec Digital Monitoring System (transcutaneous CO2 monitor)
Lawrence Rhein, SenTec AG, Ringstrasse 39, CH-4106 Therwil
Chronic Lung Disease of Prematurity, Bronchopulmonary Dysplasia, Premature Lungs
08/24
08/24
NCT06624176: ShotBlocker During Intramuscular Injection Randomized Control Trial

Recruiting
N/A
200
US
Bionix ShotBlocker, Swaddling, Sucrose administration, Masimo Rad-97 Oximeter probe
Lauren Fortier
Neonatal Pain
03/25
04/25
NCT05205356: VIGOR: Virtual Genome Center for Infant Health

Recruiting
N/A
750
US
Boston Children's Hospital, Boston Medical Center, Baystate Medical Center, UMASS Memorial Medical Center, The Cooper Health System, National Human Genome Research Institute (NHGRI), DHR Health Institute for Research and Development, The Hospitals of Providence East Campus, The Hospitals of Providence Memorial Campus, Jackson Health System, University of Texas, USA Children's and Women's Hospital
Genetics Disease, Genetics/Birth Defects, Genetic Predisposition to Disease
11/26
03/27
Donahue, Kevin
NCT05223725: Gene Therapy for Post-Operative Atrial Fibrillation

Suspended
1
78
US
AdKCNH2-G628S
Kevin Donahue, National Heart, Lung, and Blood Institute (NHLBI)
Atrial Fibrillation, Post-operative Atrial Fibrillation
08/25
08/26
Howard, Theresa
NCT01940094: The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach

Completed
3
159
Canada, US
5 mg Prednisone, •5 mg/day glucocorticoids, •5 mg/day prednisone, •5 mg/day steroids, 0 mg Prednisone
University of Pennsylvania, National Heart, Lung, and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Office of Rare Diseases (ORD), National Center for Advancing Translational Sciences (NCATS), Rare Diseases Clinical Research Network
Granulomatosis With Polyangiitis
12/24
12/24
NCT02939573: A Randomized Multicenter Study for Isolated Skin Vasculitis

Recruiting
2
90
Canada, Japan, US
Colchicine, Colcrys, Dapsone, DDS, Diaminodiphenylsulfone, Azathioprine, Imuran
University of Pennsylvania, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Advancing Translational Sciences (NCATS), Office of Rare Diseases (ORD)
Primary Cutaneous Vasculitis, Cutaneous Polyarteritis Nodosa, IgA Vasculitis, Henoch-Schönlein Purpura
12/25
12/25
CAB-201-003, NCT06328777: RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

Recruiting
1/2
12
US
CABA-201
Cabaletta Bio
Systemic Sclerosis, Scleroderma
07/29
07/29
RESET-SLE, NCT06121297: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Recruiting
1/2
12
Europe, US
CABA-201
Cabaletta Bio
Systemic Lupus Erythematosus, Lupus Nephritis
12/27
12/27
McManus, David
NCT05223725: Gene Therapy for Post-Operative Atrial Fibrillation

Suspended
1
78
US
AdKCNH2-G628S
Kevin Donahue, National Heart, Lung, and Blood Institute (NHLBI)
Atrial Fibrillation, Post-operative Atrial Fibrillation
08/25
08/26
SAGE-AF, NCT03479281: Study Fibrillation () Study

Recruiting
N/A
1200
US
University of Massachusetts, Worcester
Atrial Fibrillation
01/20
01/20
Sinha, Bharati
NCT05205356: VIGOR: Virtual Genome Center for Infant Health

Recruiting
N/A
750
US
Boston Children's Hospital, Boston Medical Center, Baystate Medical Center, UMASS Memorial Medical Center, The Cooper Health System, National Human Genome Research Institute (NHGRI), DHR Health Institute for Research and Development, The Hospitals of Providence East Campus, The Hospitals of Providence Memorial Campus, Jackson Health System, University of Texas, USA Children's and Women's Hospital
Genetics Disease, Genetics/Birth Defects, Genetic Predisposition to Disease
11/26
03/27
Selle, Matthew
BEAT-MS, NCT04047628: Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis

Recruiting
3
156
US
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Best Available Therapy (BAT), natalizumab (Tysabri®), alemtuzumab (Campath®, Lemtrada®), ocrelizumab (Ocrevus®), rituximab (Rituxan®), cladribine (Mavenclad®), ofatumumab (Kesimpta®), ublituximab (BRIUMVI™)
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Blood and Marrow Transplant Clinical Trials Network, PPD DEVELOPMENT, LP, Rho Federal Systems Division, Inc.
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
10/26
10/29
NCT06581198: A Study of Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN)

Recruiting
2
144
Europe, Japan, US, RoW
rapcabtagene autoleucel Regimen 1, rapcabtagene autoleucel Regimen 2, Standard of Care
Novartis Pharmaceuticals
Lupus Erythematosus, Systemic, Lupus Nephritis
05/29
05/30
RESET-Myositis, NCT06154252: an Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

Recruiting
1/2
24
Europe, US
CABA-201 following preconditioning with fludarabine and cyclophosphamide
Cabaletta Bio
Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Juvenile Dermatomyositis, Juvenile Polymyositis, Juvenile Idiopathic Inflammatory Myopathy (JIIM), Juvenile Myositis
07/28
07/28
CAB-201-003, NCT06328777: RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

Recruiting
1/2
12
US
CABA-201
Cabaletta Bio
Systemic Sclerosis, Scleroderma
07/29
07/29
RESET-MG, NCT06359041: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

Recruiting
1/2
12
US
CABA-201
Cabaletta Bio
Generalized Myasthenia Gravis (gMG)
09/29
09/29
RESET-SLE, NCT06121297: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Recruiting
1/2
12
Europe, US
CABA-201
Cabaletta Bio
Systemic Lupus Erythematosus, Lupus Nephritis
12/27
12/27

Download Options